Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Medical Officer | July 10, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date July 10, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 372,406 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Exercise / conversion · Acquired 15,325 · Balance 379,803 F1: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023. Row 2 · 2026-07-10 · Tax withholding · Disposed 7,397 · Balance 372,406 F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023.
F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 13, 2026 20:33 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 7,397 | $4.06 | $30,031.82 |
DisclosureSEC source: 0001470831-26-000705 · wk-form4_1783974826.xml · nonDerivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,406 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 20:33 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000705 · wk-form4_1783974826.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 16,579 | $1.89 | $31,334.31 |
DisclosureSEC source: 0001470831-26-000176 · wk-form4_1771452289.xml · nonDerivative · entry 3 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,803 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 30,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000176 · wk-form4_1771452289.xml · nonDerivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 14, 2024 and February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000176 · wk-form4_1771452289.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,382 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Read SEC document |
| January 16, 2026 Filed Jan 16, 2026 21:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 10,000 | $2.22 | $22,200.00 |
DisclosureSEC source: 0001470831-26-000045 · wk-form4_1768598875.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,382 Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 7,382 | $1.99 | $14,690.18 |
DisclosureSEC source: 0001662579-25-000055 · wk-form4_1752524362.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,382 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 13:00 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 7,382 | $1.99 | $14,690.18 |
DisclosureSEC source: 0001662579-25-000057 · wk-form4a_1752584408.xml · nonDerivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,382 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 13:00 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 15,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000057 · wk-form4a_1752584408.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment to the Form 4 originally filed on July 14, 2025 is being filed voluntarily to report the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 130,600 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001662579-25-000014 · wk-form4_1739915661.xml · derivative · entry 3 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,600 Underlying: Common Stock · 130,600 shares Expires 2035-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 5,145 | $3.18 | $16,361.10 |
DisclosureSEC source: 0001662579-25-000014 · wk-form4_1739915661.xml · nonDerivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,764 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 87,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000014 · wk-form4_1739915661.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,909 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Read SEC document |
| July 10, 2024 Filed Jul 11, 2024 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 6,191 | $5.00 | $30,955.00 |
DisclosureSEC source: 0001662579-24-000066 · wk-form4_1720728978.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,809 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 165,300 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001662579-24-000019 · wk-form4_1708034873.xml · derivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,300 Underlying: Common Stock · 165,300 shares Expires 2034-02-13 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 36,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000019 · wk-form4_1708034873.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,000 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:06 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 276,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662579-23-000074 · wk-form4_1689192375.xml · derivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,000 Underlying: Common Stock · 276,000 shares Expires 2033-07-09 F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on July 10, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:06 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 61,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000074 · wk-form4_1689192375.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,300 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on July 10, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.